Probiotic plus chemo and immunotherapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a probiotic (Lactobacillus johnsonii), two chemotherapy drugs (CapeOX), and an immunotherapy (pembrolizumab) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. It aims to see if this mix can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have metastatic colorectal cancer that is MSS or pMMR type (a certain gene pattern).
- You have tried and failed at least two standard treatments (like chemotherapy with or without targeted therapy).
- You have not taken antibiotics in the last 4 weeks.
- You do not have other active cancers, autoimmune diseases, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a probiotic (Lactobacillus Johnsonii) to standard chemotherapy and immunotherapy can help people with certain advanced solid tumors that have stopped responding to prior immunotherapy. It may help your immune system work better against the cancer.
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.